

FIRST TIME GENERIC APPROVAL

Brand Name	Narcon®
Generic Name	naloxone hydrochloride
Drug Manufacturer	Sandoz Inc

New Drug Approval

TYPE OF CLINICAL UPDATE

First Time Generic

FDA APPROVAL DATE

December 22,2021

LAUNCH DATE

December 22, 2021

REVIEW DESIGNATION

New Drug Application (NDA):208411

TYPE OF REVIEW

N/A

DISPENSING RESTRICTIONS

N/A

Overview

INDICATION FOR USE

- Naloxone HCl Nasal Spray is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.
- Naloxone HCl Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present.
- Naloxone HCl Nasal Spray is not a substitute for emergency medical care.

MECHANISMS OF ACTION

Naloxone hydrochloride is an opioid antagonist that antagonizes opioid effects by competing for the same receptor sites. Naloxone hydrochloride reverses the effects of opioids, including respiratory depression, sedation, and hypotension. It can also reverse the psychotomimetic and dysphoric effects of agonist-antagonists such as pentazocine.

DOSE FORM AND STRENGTH

Nasal spray: 4 mg of naloxone hydrochloride in 0.1 mL.

This document is designed to be an informational resource to facilitate discussion and should be used neither as a basis for clinical decision-making or treatment nor as a substitute for reading original literature. RxAdvance makes every effort to ensure that the information provided is up-to-date, accurate, and complete, but no guarantee is made to that effect. If this information is provided to clients or vendors, it is subject to any contractual confidentiality provisions. Third-party disclosures are in violation of confidentiality provisions.

FIRST TIME GENERIC APPROVAL

DOSE & ADMINISTRATION

Administration of a single spray of naloxone HCl Nasal Spray intranasally into one nostril and administer additional doses of naloxone HCl Nasal Spray, using a new nasal spray with each dose, if the patient does not respond or responds and then relapses into respiratory depression, additional doses of naloxone HCl Nasal Spray may be given every 2 to 3 minutes until emergency medical assistance arrives.

This document is designed to be an informational resource to facilitate discussion and should be used neither as a basis for clinical decision-making or treatment nor as a substitute for reading original literature. RxAdvance makes every effort to ensure that the information provided is up-to-date, accurate, and complete, but no guarantee is made to that effect. If this information is provided to clients or vendors, it is subject to any contractual confidentiality provisions. Third-party disclosures are in violation of confidentiality provisions.